|
Telik, Inc. of Palo Alto, CA is an innovative biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company’s most advanced investigational drug candidates in clinical development are TELINTRA® (Ezatiostat HCl, TLK199) for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA® (Canfosfamide HCl, TLK286) for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP™, which enables the rapid and efficient discovery of small molecule drug candidates.
August 21, 2008
TELIK’S Proteasome Inhibitor Program Meets a Preclinical Development Milestone
August 21, 2008
TELIK’S Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
August 19, 2008
Telik Announces Diabetes License Agreement with ReceptorBio
|
